Loading clinical trials...

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

A Double-Blind, Multicenter, Placebo and Active-Controlled, Acute Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder

NCT00048607•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

Detailed Description

The duration of treatment is 8 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with Major Depressive Disorder

Key Dates

Start Date

July 30, 2002

Primary Completion Date

December 31, 2003

Completion Date

December 31, 2003

Last Updated

May 5, 2017

Enrollment

600

ACTUAL participants

Conditions

Major Depressive Disorder

Interventions

aprepitant

DRUG

Comparator: paroxetine HCL

DRUG

Comparator: Placebo (Unspecified)

DRUG

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 5, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

Inclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)